Key points:
- TransCode Therapeutics reported positive preclinical results for TTX-MC138
- The company evaluated the bioactivity of the drug
- TransCode Shares surged premarket
TransCode Therapeutics (NASDAQ: RNAZ) shares have surged to levels last seen in August after the company reported positive preclinical results for its lead candidate, TTX-MC138, in Pancreatic Adenocarcinoma.
TransCode’s stock price is trading 37.5% higher premarket at $1.49 per share, pushing up from its recent lows. The company’s shares have fallen over 61% in the last 12 months and more than 57% in 2022.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Also Read: The Best Biotech Penny Stocks under $5 to Buy Right Now
The company revealed Tuesday that it evaluated the bioactivity of TTX-MC138 in a “murine model of pancreatic adenocarcinoma.”
The study saw mice, carrying human pancreatic tumors implanted in their pancreas, treated once weekly for 10 weeks with TTX-MC138. The drug was said to have demonstrated a pharmacodynamic response by successfully inhibiting its target.
The company added that 40% of animals treated with TTX-MC138 had complete responses, and further studies to better find the ideal dose and therapeutic window in pancreatic cancer are ongoing.
TransCode co-founder and CTO Zdravka Medarova said the data supports the “advancement of TTX-MC138 into the clinic.”
Michael Dudley, the company’s co-founder, president and CEO, commented: “Demonstrating successful treatment using our first-in-class RNA-targeted therapeutic candidate in a variety of solid tumor models is an important step in the preclinical development process and, we believe, further de-risks our approach,”
“As we have previously indicated, we are on track to submit an exploratory Investigational New Drug Application (eIND) this year for our planned Phase 0 first-in-human (FIH) clinical trial with TTX-MC138 in cancer patients with advanced solid tumors.”
